<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240045</url>
  </required_header>
  <id_info>
    <org_study_id>VB-PG-007</org_study_id>
    <nct_id>NCT00240045</nct_id>
  </id_info>
  <brief_title>The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction</brief_title>
  <official_title>The Use of Midodrine, Octreotide and Albumin in Refractory Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are
      mediated in part by diminished circulatory volume and that treatment with midodrine,
      octreotide and albumin can improve renal and patient outcomes by restoring effective
      circulating volume and systemic perfusion.

      Our primary objective is to assess change in creatinine clearance using inulin. We will
      enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and
      exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR,
      albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before,
      during, and after initiation of drug and compared.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in renal function (creatinine)</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ascites control</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Type 2 Hepatorenal Syndrome</condition>
  <condition>Refractory Ascites</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine, albumin, octreotide LAR</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midodrine, octreotide, albumin</intervention_name>
    <description>midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis (biopsy or compatible clinical (ascites, varices), laboratory (low albumin,
             elevated bilirubin, elevated INR) and radiologic data (nodular appearing liver on
             ultrasound)).

        Type 2 hepatorenal syndrome and/or refractory ascites

        Exclusion Criteria:

          -  Secondary causes of renal dysfunction (proteinuria &gt;500 mg/day, active urinary
             sediment, abnormal renal ultrasound, nephrotoxic medications) Bacterial infection
             (positive blood, urine or ascites cultures) within the past 2 weeks Gastrointestinal
             hemorrhage or encephalopathy within the past 2 weeks Age &lt;18 Transvenous intrahepatic
             portosystemic stent shunt (TIPS) Hepatocellular carcinoma beyond the Milan criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Bain, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>December 3, 2007</last_update_submitted>
  <last_update_submitted_qc>December 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2007</last_update_posted>
  <responsible_party>
    <name_title>Dr. Vince Bain</name_title>
    <organization>University of Alberta</organization>
  </responsible_party>
  <keyword>Hepatorenal syndrome</keyword>
  <keyword>Refractory ascites</keyword>
  <keyword>Midodrine</keyword>
  <keyword>Octreotide</keyword>
  <keyword>Albumin</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

